Trial Profile
A Phase I study of intratumoral administration of TDM-812 in patients with treatment-resistant breast cancer (RPN2siRNA)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Apr 2018
Price :
$35
*
At a glance
- Drugs TDM 812 (Primary)
- Indications Advanced breast cancer; Ductal carcinoma; Triple negative breast cancer
- Focus Adverse reactions; First in man
- 30 Mar 2018 Status changed to completed.
- 14 Sep 2017 Status changed from recruiting to discontinued.
- 13 Mar 2017 Planned End Date changed from 30 Sep 2017 to 31 Jan 2018.